



SEQUENCE LISTING

Bayer Pharmaceuticals Corporation
Eveleigh, Deepa
Taylor, Ian

<120> METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING
CANCER THERAPY

<130> 5138

<140> US 10/675,406

<141> 2003-09-30

<150> US 60/415,194

<151> 2002-09-30

<160> 7

<170> PatentIn version 3.2

<210> 1

<211> 1449

<212> DNA

<213> Homo sapiens

<400> 1

ctggatagaa cagctcaagc cttgccactt cgggctttctc actgcagctg ggcttggact	60
tcggagtttt gccattgcca gtgggacgtc tgagactttc tccttcaagt acttggcaga	120
tcactctctt agcaggggtct gcgcttcgca gccgggatga agctggtttc cgtcgccctg	180
atgtacctgg gttcgctcgc cttcctaggc gctgacaccg ctcggttgga tgtcgcgctc	240
gagtttcgaa agaagtggaa taagtgggct ctgagtcgtg ggaagagggg actgcggatg	300
tccagcagct accccaccgg gctcgctgac gtgaaggccg ggcctgcca gacccttatt	360
cggccccagg acatgaaggg tgcctctcga agccccgaag acagcagtcc ggatgccgcc	420
cgcattccgag tcaagcgcta ccgccagagc atgaacaact tccagggcct ccggagcttt	480
ggctgccgct tcgggacgtg cacggtgcag aagctggcac accagatcta ccagttcaca	540
gataaggaca aggacaacgt cgcccccagg agcaagatca gccccagggg ctacggccgc	600
cggcgccggc gctccctgcc cgaggccggc ccgggtcgga ctctggtgtc ttctaagcca	660
caagcacacg gggctccagc cccccgagt ggaagtgtc cccactttct ttaggattta	720
ggcgcccatg gtacaaggaa tagtcgcgca agcatcccgc tggcgcctcc cgggacgaag	780
gacttcccga gcggtgtggg gaccgggctc tgacagccct gcggagacct tgagtccggg	840
aggcaccgtc cggcggcgag ctctggcttt gcaagggccc ctcttcttgg gggcttcgct	900
tccttagcct tgctcaggtg caagtgcgcc agggggcggg gtgcagaaga atccgagtgt	960
ttgccaggct taaggagagg agaaactgag aatgaatgc tgagaccccc ggagcagggg	1020
tctgagccac agccgtgtc gccacaaac tgattttctca cggcgtgtca ccccaccagg	1080
gcgcaagcct cactattact tgaactttcc aaaacctaaa gaggaaaagt gcaatgcgtg	1140

ttgtacatac agaggtaact atcaatattt aagtttgttg ctgtcaagat tttttttgta 1200
 acttcaaata tagagatatt tttgtacgtt atatattgta ttaagggcat tttaaaagca 1260
 attatattgt cctcccctat ttttaagacgt gaatgtctca gcgagggtgta aagttgttcg 1320
 ccgcgtggaa tgtgagtgtg tttgtgtgca tgaaagagaa agactgatta cctcctgtgt 1380
 ggaagaagga aacaccgagt ctctgtataa tctatttaca taaaatgggt gatatgcgaa 1440
 cagcaaacc 1449

<210> 2
 <211> 23
 <212> DNA
 <213> Artificial

<220>
 <223> Primer

<400> 2
 gtgaatgtct cagcgagggtg taa 23

<210> 3
 <211> 24
 <212> DNA
 <213> Artificial

<220>
 <223> Primer

<400> 3
 ccttcttcca cacaggaggt aatc 24

<210> 4
 <211> 23
 <212> DNA
 <213> Artificial

<220>
 <223> Primer

<400> 4
 ttcgccgcgt ggaatgtgag tgt 23

<210> 5
 <211> 23
 <212> DNA
 <213> Artificial

<220>
 <223> Primer

<400> 5
 gtgaatgtct cagcgagggtg taa 23

<210> 6
 <211> 24

<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 6
ccttcttcca cacaggaggt aatc

24

<210> 7
<211> 185
<212> PRT
<213> Homo sapiens

<400> 7

Met Lys Leu Val Ser Val Ala Leu Met Tyr Leu Gly Ser Leu Ala Phe
1 5 10 15

Leu Gly Ala Asp Thr Ala Arg Leu Asp Val Ala Ser Glu Phe Arg Lys
20 25 30

Lys Trp Asn Lys Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Arg Met
35 40 45

Ser Ser Ser Tyr Pro Thr Gly Leu Ala Asp Val Lys Ala Gly Pro Ala
50 55 60

Gln Thr Leu Ile Arg Pro Gln Asp Met Lys Gly Ala Ser Arg Ser Pro
65 70 75 80

Glu Asp Ser Ser Pro Asp Ala Ala Arg Ile Arg Val Lys Arg Tyr Arg
85 90 95

Gln Ser Met Asn Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys Arg Phe
100 105 110


Gly Thr Cys Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr
115 120 125

Asp Lys Asp Lys Asp Asn Val Ala Pro Arg Ser Lys Ile Ser Pro Gln
130 135 140

Gly Tyr Gly Arg Arg Arg Arg Arg Ser Leu Pro Glu Ala Gly Pro Gly
145 150 155 160

Arg Thr Leu Val Ser Ser Lys Pro Gln Ala His Gly Ala Pro Ala Pro
165 170 175

Pro Ser Gly Ser Ala Pro His Phe Leu
180 185



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/675,406
Source: Oipe
Date Processed by STIC: 10-10-03

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkr41note.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry directly to (EFFECTIVE 12/01/2003):
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 10/08/2003

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: 101675,404
ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE		
1 ____ Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."	
2 ____ Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.	
3 ____ Misaligned Amino Numbering	The numbering under each 5 th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.	
4 ____ Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.	
5 ____ Variable Length	Sequence(s) ____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.	
6 ____ PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.	
7 ____ Skipped Sequences (OLD RULES)	Sequence(s) ____ missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.	
8 ____ Skipped Sequences (NEW RULES)	Sequence(s) ____ missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000	
9 ____ Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.	
10 ____ Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence	
11 ____ Use of <220>	Sequence(s) ____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)	
12 ____ PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.	
13 ____ Misuse of n/Xaa	"n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid	



IFWO

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/675,406

DATE: 10/10/2003
TIME: 15:01:27

Input Set : A:\5138.txt
Output Set: N:\CRF4\10102003\J675406.raw

3 <110> APPLICANT: Bayer Pharmaceuticals Corporation
4 Eveleigh, Deepa
5 Taylor, Ian
7 <120> TITLE OF INVENTION: METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND
MONITORING

8 CANCER THERAPY
10 <130> FILE REFERENCE: 5138
C--> 12 <140> CURRENT APPLICATION NUMBER: US/10/675,406
C--> 12 <141> CURRENT FILING DATE: 2003-09-30
12 <150> PRIOR APPLICATION NUMBER: US 60/415,194
13 <151> PRIOR FILING DATE: 2002-09-30
15 <160> NUMBER OF SEQ ID NOS: 7
17 <170> SOFTWARE: PatentIn version 3.2
19 <210> SEQ ID NO: 1
20 <211> LENGTH: 1449
21 <212> TYPE: DNA
22 <213> ORGANISM: Homo sapiens
24 <400> SEQUENCE: 1

Does Not Comply
Corrected Diskette Needed

25	ctggatagaa	cagctcaage	cttgcactt	cggtcttctc	actgcagctg	ggcttggact	60
27	tcggagtttt	gccattgcc	gtgggacgtc	tgagactttc	tccttcaagt	acttggcaga	120
29	tcactctctt	agcaggggtc	gcgcttgcga	gccgggatga	agctgggttc	cgtcgcctcg	180
31	atgtacctgg	gttcgctcgc	cttcctaggg	gctgacaccg	ctcggttgg	tgctcgctcg	240
33	gagtttcgaa	agaagtggaa	taagtgggt	ctgagtcgtg	ggaagaggga	actgcggatg	300
35	tccagcagct	accccaccgg	gctcgtctgc	gtgaaggccg	ggcctgccc	gaccttatt	360
37	cggccccagg	acatgaagg	tgctctcga	agccccgaag	acagcagtc	ggatgccgc	420
39	cgcatecgag	tcaagcgeta	ccgccagagc	atgaacaact	tccagggcct	ccgagcttt	480
41	ggctgcccgt	tcgggacgtg	cacggtgcag	aagctggcac	accagatcta	ccagttcaca	540
43	gataaggaca	aggacaacgt	cgcgccccagg	agcaagatca	gcccccagg	ctacggccgc	600
45	cggcgccggc	gctccctgcc	cgaggccggc	cggggtcgga	ctctgggtgc	ttctaagcca	660
47	caagcacacg	gggtccagc	ccccccgagt	ggaagtgtc	cccactttct	ttaggattta	720
49	ggcgccccatg	gtacaaggaa	tagtcgcgca	agcatcccgc	tggtgcctcc	cgggacgaag	780
51	gacttcccga	gcgggtgtgg	gaccgggctc	tgacagccct	gcggagacct	tgagtcggg	840
53	aggcaccgtc	cggcgccgag	ctctggcttt	gcaagggcc	ctccttctgg	gggttctcgt	900
55	tccttagcct	tgctcaggtg	caagtcccc	agggggcggg	gtgcagaaga	atccgagtgt	960
57	ttgccaggct	taaggagagg	agaaactgag	aatgaatgc	tgagaccccc	ggagcagggg	1020
59	tctgagccac	agccgtgctc	gccacaaac	tgattttctca	cggcgtgtca	ccccaccagg	1080
61	gcgcaagcct	cactattact	tgaactttcc	aaaacctaaa	gaggaaaagt	gcaatgcgtg	1140
63	ttgtacatac	agaggtaact	atcaatat	aagtttgttg	ctgtcaagat	tttttttgta	1200
65	acttcaaata	tagagatatt	tttgtagctt	atatattgta	ttaagggc	tttaaaagca	1260
67	attatattgt	cctccctat	tttaagagct	gaatgtctca	gcgaggtgta	aagttgttcg	1320
69	cgcgctggaa	tgtgagtgtg	tttgtgtgca	tgaagagaaa	agactgatta	cctcctgtgt	1380
71	ggaagaagga	aacaccgagt	ctctgtataa	tctattttaca	taaaatgggt	gatatgcgaa	1440
73	cagcaaacc						1449
76	<210>	SEQ ID NO: 2					

RAW SEQUENCE LISTING

DATE: 10/10/2003

PATENT APPLICATION: US/10/675,406

TIME: 15:01:27

Input Set : A:\5138.txt

Output Set: N:\CRF4\10102003\J675406.raw

77 <211> LENGTH: 23
 78 <212> TYPE: DNA
 79 <213> ORGANISM: Primer *see item 10 on error summary sheet -*
 81 <400> SEQUENCE: 2
 82 gtgaatgtct cagcgaggtg taa 23
 85 <210> SEQ ID NO: 3
 86 <211> LENGTH: 24
 87 <212> TYPE: DNA
 88 <213> ORGANISM: Primer
 90 <400> SEQUENCE: 3
 91 ccttcttcca cacaggaggt aatc 24
 94 <210> SEQ ID NO: 4
 95 <211> LENGTH: 23
 96 <212> TYPE: DNA
 97 <213> ORGANISM: Primer
 99 <400> SEQUENCE: 4
 100 ttgcgcgcgt ggaatgtgag tgt 23
 103 <210> SEQ ID NO: 5
 104 <211> LENGTH: 23
 105 <212> TYPE: DNA
 106 <213> ORGANISM: Primer
 108 <400> SEQUENCE: 5
 109 gtgaatgtct cagcgaggtg taa 23
 112 <210> SEQ ID NO: 6
 113 <211> LENGTH: 24
 114 <212> TYPE: DNA
 115 <213> ORGANISM: Primer
 117 <400> SEQUENCE: 6
 118 ccttcttcca cacaggaggt aatc 24
 121 <210> SEQ ID NO: 7
 122 <211> LENGTH: 185
 123 <212> TYPE: PRT
 124 <213> ORGANISM: Homo sapiens
 126 <400> SEQUENCE: 7
 128 Met Lys Leu Val Ser Val Ala Leu Met Tyr Leu Gly Ser Leu Ala Phe
 129 1 5 10 15
 132 Leu Gly Ala Asp Thr Ala Arg Leu Asp Val Ala Ser Glu Phe Arg Lys
 133 20 25 30
 136 Lys Trp Asn Lys Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Arg Met
 137 35 40 45
 140 Ser Ser Ser Tyr Pro Thr Gly Leu Ala Asp Val Lys Ala Gly Pro Ala
 141 50 55 60
 144 Gln Thr Leu Ile Arg Pro Gln Asp Met Lys Gly Ala Ser Arg Ser Pro
 145 65 70 75 80
 148 Glu Asp Ser Ser Pro Asp Ala Ala Arg Ile Arg Val Lys Arg Tyr Arg
 149 85 90 95
 152 Gln Ser Met Asn Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys Arg Phe
 153 100 105 110
 156 Gly Thr Cys Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr

DATE: 10/10/2003

PATENT APPLICATION: US/10/675,406

TIME: 15:01:27

Input Set : A:\5138.txt

Output Set: N:\CRF4\10102003\J675406.raw

file:///C:/CRF4/Outhold/VsrJ675406.htm

VERIFICATION SUMMARY

DATE: 10/10/2003

PATENT APPLICATION: US/10/675,406

TIME: 15:01:28

Input Set : A:\5138.txt

Output Set: N:\CRF4\10102003\J675406.raw

L:12 M:270 C: Current Application Number differs, Replaced Current Application No
L:12 M:271 C: Current Filing Date differs, Replaced Current Filing Date